Tumor-specific antivascular effect of TZT-1027 (Soblidotin) elucidated by magnetic resonance imaging and confocal laser scanning microscopy

Cancer Science

Volumn 98, Issue 4, 2007, Pages 598-604

  Natsume, Tsugitaka ^a   Watanabe, Junichi ^a   Ogawa, Kenji ^b   Yasumura, Kazuhiko ^b   Kobayashi, Motohiro ^a  

^a Grelan Pharmaceutical Co Ltd   (Japan)

^b NIPPON KOKAN HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AURISTATIN PE; DIMETHYLBENZ[A]ANTHRACENE; DOCETAXEL; EVANS BLUE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL INJURY; BREAST CANCER; CANCER TRANSPLANTATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DEATH; DRUG DOSE COMPARISON; DRUG SPECIFICITY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN TISSUE; INHIBITION KINETICS; KIDNEY PARENCHYMA; MICROVASCULATURE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TREATMENT OUTCOME; TUMOR BLOOD FLOW; TUMOR NECROSIS; TUMOR REGRESSION; TUMOR VASCULARIZATION; TUMOR VOLUME; WEIGHT REDUCTION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; OLIGOPEPTIDES; RATS; RATS, NUDE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34147101261     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00418.x     Document Type: Article

References (34)

1. Miyazaki K, Kobayashi M, Natsume T et al. Synthesis and antitumor activity of novel dolastatin 10 analogs. Chem Pharm Bull 1995; 43: 1706-18.
2. Pettit GR, Kamano Y, Herald CL et al. The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin 10. J Am Chem Soc 1987; 109: 6883-5.
3. Kobayashi M, Natsume T, Tamaoki S et al. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Res 1997; 88: 316-27.
4. Natsume T, Watanabe J, Tamaoki S, Fujio N, Miyasaka K, Kobayashi M. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin. Jpn J Cancer Res 2000; 91: 737-47.
5. Watanabe J, Natsume T, Fujio N, Miyasaka K, Kobayashi M. Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. Apoptosis 2000; 5: 345-53.
6. Natsume T, Watanabe J, Koh Y et al. Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo. Cancer Sci 2003; 94: 826-33.
7. Watanabe J, Minami M, Kobayashi M. Antitumor activity of TZT-1027 (Soblidotin). Anticancer Res 2006; 26: 1973-82.
8. Natsume T, Watanabe J, Horiuchi T, Kobayashi M. Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs. Anticancer Res 2006; 26: 1145-52.
9. Watanabe J, Natsume T, Kobayashi M. Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma. Cancer Sci 2006; 97: 1410-6.
10. Otani M, Natsume T, Watanabe J et al. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 2000; 91: 837-44.
11. Kobayashi M, Natsume T, Watanabe J et al. Activity of a novel antitumor agent, TZT-1027. Nippon Yakurigaku Zasshi (Japanese) 1999; 114 (Suppl): 230-5.
12. Yamamoto N, Andoh M, Kawahara M, Fukuoka M, Niitani H. Phase I study of TZT-1027, an inhibitor of tubulin polymerization, given weekly × 3 as a 1-hour intravenous infusion in patients (pts) with solid tumors [abstract]. Proc Am Soc Clin Oncol 2002; 21: S420.
13. Scfoeffski P, Thate B, Beutel G et al. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 2004; 15: 671-9.
14. De Jonge MJA, Van der Gaast A, Planting AST et al. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res 2005; 11: 3806-13.
15. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
16. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 1993; 29: 1320-4.
17. Sally AH, Louise ES, Chaplin DJ. Anti-vascular approaches to solid tumor therapy. Int J Cancer 1995; 63: 119-23.
18. Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents. Br J Cancer Supplement 1996; 27: 86-8.
19. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57: 1829-34.
20. Tozer GM, Prise VE, Wilson J et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res 1999; 59: 1626-34.
21. Goertz DEYuJL, Kerbel RS, Burns PN, Foster FS. High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res 2002; 62: 6371-5.
22. Davis PD, Dougherty GJ, Blakey DC et al. ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002; 62: 7247-53.
23. Nihei Y, Suga Y, Morinaga Y et al. A novel combretastatin A-4 derivative Ac7700, shows marked antitumor activity against solid tumors and orthotopically transplanted tumors. Jpn J Cancer Res 1999; 90: 1016-25.
24. Thrope PE, Chaplin DJ, Blakey DC. The first international conference on vascular targeting: Meeting overview. Cancer Res 2003; 63: 1144-7.
25. Thrope PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10: 415-27.
26. Yasumura K, Ogawa K, Nakagawa Y et al. Dynamic MR imaging and tumor angiogenesis in DMBA-induced rat breast cancer: Three dimensional (3D) reconstructed image analysis of tumor microvessels by confocal laser scanning microscopy. Breast Cancer 1997; 4: 291-6.
27. Gillies RJ, Bhujwalla ZM, Evelhoch J et al. Applications of magnetic resonance in model systems: Tumor biology and physiology. Neoplasia 2000; 2: 139-51.
28. Thoeny HC, De Keyzer F, Chen F et al. Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia 2005; 7: 779-87.
29. Robinson SP, Kalber TL, Howe FA et al. Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. Neoplasia 2005; 7: 466-74.
30. Geran RJ, Greenberg NR, MacDonald HM, Schumacher AM, Abott BY. Protocols for screening chemical agents and natural products against animal tumor and other biological systems, 3rd edn. Cancer Chemother Rep 1972; 3: 1-103.
31. Goldin A, Venditti JM, Macdonald JS, Muggia FM, Henney JE, Devita VT Jr. Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur J Cancer 1981; 17: 129-42.
32. Huggins C, Grand LC, Brillantes FP. Mammary cancer induced by a single feeding of polymucular hydrocarbons, and its suppression. Nature 1961; 189: 204-7.
33. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83: 288-91.
34. Thun-Battersby S, Mevissen M, Loscher W. Exposure of Sprague-Dawley rats to a 50-Hertz, 100-microTesla magnetic field for 27 weeks facilitates mammary tumorigenesis in the 7,12-dimethylbenz[a]-anthracene model of breast cancer. Cancer Res 1999; 59: 3627-33.